On 06 October 2011 the first patient with chronic pancreatits was dosed in a phase II clinical study that evaluates the efficacy of Namisol® on the treatment of pain in chronic pancreatitis patients suffering from persistent abdominal pain. This study is conducted by the University Medical Center (UMC) St. Radboud under supervision of the investigators Dr. H. van Goor and Dr. O.H.G. Wilder-Smith as a part of a research program performed by a consortium in which UMC St. Radboud and Echo Pharmaceuticals participate. The study is expected to be completed Q1 2013.